[Lee R, Wong TY, Sabanayagam C (2015)] Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond); 2:17.
[ETDRS Research Group (1985)] Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol; 103(12):1796-806.
[Smiddy WE (2011)] Economic considerations of macular edema therapies. Ophthalmology; 118(9):1827-33.
[Virgili G, Parravano M, Menchini F, et al. (2014)] Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?. Br J Ophthalmol; 98(4):421-2.
[Agarwal A, Sarwar S, Sepah YJ, et al. (2015)] What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?. Curr Opin Ophthalmol; 26(3):177-83.
Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies. Presented at: The Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. May 2021.
Data on file. KESTREL (year two) first interpretable results. Novartis, 2021.
Data on file. KESTREL clinical trial protocol (CRTH258B2301). Novartis, 2021.
Data on file. KITE clinical trial protocol (CRTH258B2302). Novartis, 2021.